Management of refractory ulcerative colitis

Current Treatment Options in Gastroenterology

Volumn 9, Issue 3, 2006, Pages 234-245

  Sohi, Sunana ^b   Cohen, Russell D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; CORTICOSTEROID; CYCLOSPORIN; FERROUS SULFATE; FOLIC ACID; INFLIXIMAB; IRON COMPLEX; LAXATIVE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MLN 02; MULTIVITAMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; PURINE DERIVATIVE; SORBITOL; TACROLIMUS; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL PAIN; ALOPECIA; ANAPHYLAXIS; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; CELIAC DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON MUCOSA; CONFUSION; CONSTIPATION; COUGHING; CROHN DISEASE; DIAGNOSTIC ERROR; DIARRHEA; DIET; DIVERTICULITIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG USE; EMOTION; FEVER; GASTRITIS; GINGIVA HYPERPLASIA; HEADACHE; HEALTH STATUS; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INTERSTITIAL LUNG DISEASE; INTESTINE INFECTION; ISCHEMIA; LEUKOPENIA; LIVER ATROPHY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LONG TERM CARE; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PANCREAS INSUFFICIENCY; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT CARE; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; REVIEW; SEIZURE; SEPSIS; SIGMOIDOSCOPY; TREATMENT PLANNING; TREATMENT WITHDRAWAL; TREMOR; ULCERATIVE COLITIS;

EID: 33744964632     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0042-3     Document Type: Review

References (54)

1. Yang A, Chen Y, Scherl E, et al.: Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis 2005, 11:528-532.
2. Ardizzone S, Molteni P, Imbesi V, et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997, 25:330-333.
3. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
4. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R: Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003, 37:220-225.
5. Matula S, Croog V, Itzkowitz S, et al.: Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005, 3:1015-1021.
6. Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9-17.
7. Dubinsky MC, Hassard PV, Seidman EG, et al.: An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181-189.
8. Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
9. Message L, Bourreille A, Laharie D, et al.: Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005, 29:231-235.
10. Rolny P, Sadik R: Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis 2002, 17:67-69.
11. Campbell S, Travis S, Jewell D: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17:79-84.
12. Actis GC, Lagget M, Rizzetto M, et al.: Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis [in Italian]. Minerva Med 2004, 95:65-70.
13. de Saussure P, Soravia C, Morel P, Hadengue A: Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005, 22:203-208.
14. Fellermann K, Tanko Z, Herrlinger KR, et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002, 8:317-324.
15. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W: Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:415-423.
16. Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201-1207.
17. Ford AC, Towler RJ, Moayyedi P, et al.: Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:1365-1369.
18. Skelly MM, Logan RF, Jenkins D, et al.: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:93-97.
19. Cummings JR, Herrlinger KR, Travis SP, et al.: Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21:385-389.
20. Te HS, Schiano TD, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150-3156.
21. Lichtenstein GR: Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001, 7:89-93.
22. Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83-88.
23. Probert CS, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998-1002.
24. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
25. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
26. Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
27. Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002, 35:151-156.
28. Harrison J, Rubenstein J, Leff A, Cohen R: A controlled trial of the impact of infliximab upon health care utilization, costs, and charges in patients with Crohn's disease [abstract]. Gastroenterology 2003, 124:A521.
29. Jewell DP, Satsangi J, Lobo A, et al.: Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005, 17:1047-1052.
30. Tulchinsky H, Hawley PR, Nicholls J: Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003, 238:229-234.
31. Meagher AP, Farouk R, Dozois RR, et al.: J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998, 85:800-803.
32. Hurst RD: Surgical management of inflammatory bowel disease. In Inflammatory Bowel Disease: Diagnosis and Therapeutics. Edited by Cohen RD. Totowa, NJ: Humana Press; 2003:157-199.
33. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
34. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacterio-therapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
35. Leong AP, Londono-Schimmer EE, Phillips RK: Life-table analysis of stomal complications following ileostomy. Br J Surg 1994, 81:727-729.
36. Bauer JJ, Gelernt IM, Salky B, Kreel I: Sexual dysfunction following proctocolectomy for benign disease of the colon and rectum. Ann Surg 1983, 197:363-367.
37. Plevy S, Salzberg B, Regueiro M, et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe, steroid-refractory ulcerative colitis: preliminary results of a phase I study [abstract]. Gastroenterology 2003, 124:A-7.
38. Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699-705.
39. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
40. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
41. Musch E, Andus T, Malek M: Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial. Aliment Pharmacol Ther 2002, 16:1233-1239.
42. Musch E, Andus T, Kruis W, et al.: Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005, 3:581-586.
43. Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
44. Kohgo Y, Hibi H, Chiba T, et al.: Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. Ther Apher 2002, 6:255-260.
45. Hanai H, Watanabe F, Takeuchi K, et al.: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28-35.
46. Naganuma M, Funakoshi S, Sakuraba A, et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251-257.
47. Kruis W, Dignass A, Steinhagen-Thiessen E, et al.: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005, 11:7001-7006.
48. Creed TJ, Norman MR, Probert CS, et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003, 18:65-75.
49. Van Assche G, Dalle I, Noman M, et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003, 98:369-376.
50. Vernia P, Annese V, Bresci G, et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244-248.
51. Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350-357.
52. Farrell RJ: Epidermal growth factor for ulcerative colitis. N Engl J Med 2003, 349:395-397.
53. Borkow G, Leng Q, Weisman Z, et al.: Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000, 106:1053-1060.
54. Summers RW, Elliott DE, Urban JF, Jr, et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825-832.